Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.

Leukemia & lymphoma - 1 Oct 2022

Hu Chaolu, Wang Xiaoqin

Abstract excerpt

Although the effect of gene mutations on overall response rate (ORR) and overall survival (OS) in myelodysplastic syndrome (MDS) treated with hypomethylating agents (HMAs) has been explored, the effect is still controversial. We performed this meta-analysis to investigate the effect. The pooled odds ratio (OR) and 95% confidence interval (CI) for ORR and the pooled hazard ratio (HR) and 95%CI for OS were chosen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Core Binding Factor Alpha 2 Subunit
Share to Mutation
Share to Myelodysplastic Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Splicing Factor U2AF

Source

Identifiers

PMID: 35543621
DOI: 10.1080/10428194.2022.2070913

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.PMID 35543621Read ↗

Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.Semantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.Semantic proximity Read ↗

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Semantic proximity Read ↗

Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes.Semantic proximity Read ↗

[Characteristics and Clinical Significance of Gene Mutation in Patients with Myelodysplastic Syndrome].Semantic proximity Read ↗

The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.Semantic proximity Read ↗

Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.Semantic proximity Read ↗

Clinical characteristics and prognostic analysis of gene mutations in Myelodysplastic SyndromeSemantic proximity Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.Semantic proximity Read ↗

Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.